ricolinostat
Small moleculeexperimental
Clinical trial activity
13 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01323751)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Cholangiocarcinoma · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Healthy Volunteers · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1
- Pain · Phase 2
- Peripheral Nervous System Diseases · Phase 1
Mechanism of action
- Histone deacetylase 6INHIBITOR
Histone deacetylase 6 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1)NO- Mol. weight
- 433.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2364628 ↗
Also known as
- 2-(diphenylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
- acy-1215
- acy-1215
- acy-1215
- acy-1215
- acy-63
- acy-63
- ricolinostat
- ricolinostat
- ricolinostat
- ricolinostat
- rocilinostat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05229042 | Phase 1 | Feb 28, 2022 | 3E Therapeutics Corporation |
| NCT05193851 | Phase 1 | Jan 12, 2022 | 3E Therapeutics Corporation |
| NCT03176472 | Phase 2 | Oct 1, 2017 | Regenacy Pharmaceuticals LLC |
| NCT02856568 | Phase 1 | May 1, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT02787369 | Phase 1 | May 1, 2016 | Acetylon Pharmaceuticals Incorporated, Harvard University |
| NCT02632071 | Phase 1 | Feb 1, 2016 | Acetylon Pharmaceuticals Incorporated, Columbia University, National Cancer Institute (NCI) |
| NCT02661815 | Phase 1 | Jan 1, 2016 | Acetylon Pharmaceuticals Incorporated, Harvard University |
| NCT02189343 | Phase 1 | Sep 15, 2014 | Celgene, University of Texas, San Antonio |
| NCT02091063 | Phase 1/Phase 2 (Phase 2) | Apr 2, 2014 | Acetylon Pharmaceuticals Incorporated, Columbia University |
| NCT02088398 | Phase 1 | Mar 1, 2014 | Acetylon Pharmaceuticals Incorporated, Covance |
| NCT01997840 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Celgene, Harvard University |
| NCT01583283 | Phase 1/Phase 2 (Phase 2) | Jul 12, 2012 | Celgene, Harvard University |
| NCT01323751 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2011 | Celgene, Emory University, The Leukemia and Lymphoma Society |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acetylon Pharmaceuticals Incorporated | For profit | 5 | 1 | 2 | 2014 |
| Celgene | For profit | 4 | 4 | 2 | 2011 |
| Harvard University | Academic/Hospital | 4 | 2 | 2 | 2012 |
| 3E Therapeutics Corporation | For profit | 2 | 2 | 1 | 2022 |
| Columbia University | Academic/Hospital | 2 | 2 | 2 | 2014 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2016 |
| Covance | For profit | 1 | 0 | 1 | 2014 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Regenacy Pharmaceuticals LLC | For profit | 1 | 1 | 1 | 2017 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2014 |
12 organizations
Page 1 / 1